3,107 results on '"Hiddemann, Wolfgang"'
Search Results
2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
3. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model
4. Prognostic impact of CEBPA mutational subgroups in adult AML
5. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
6. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
7. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
8. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
9. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
10. PARP14 is a novel target in STAT6 mutant follicular lymphoma
11. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study
12. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
13. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
14. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
15. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
16. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
17. Late Effects after Treatment of Acute Myeloid Leukemia in Childhood and Adolescence
18. A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
19. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
20. Friday leukemia—a structural phenomenon
21. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial
22. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
23. Ganzheitliche Begleitung von Krebspatienten: Supportive und komplementäre Verfahren
24. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
25. Prognostic impact of CEBPA mutational subgroups in adult AML
26. Clinical Trials with Nucleoside Analogs in Lymphomas
27. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma
28. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
29. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
30. Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML
31. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
32. The clinical mutatome of core binding factor leukemia
33. ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells
34. Loss of KDM6A confers drug resistance in acute myeloid leukemia
35. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia
36. Late Effects after Treatment of Acute Myeloid Leukemia in Childhood and Adolescence
37. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
38. P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
39. P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
40. P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
41. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles
42. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group
43. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
44. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens
45. Ectopic Expression of the Homeobox Gene Cdx2 Is the Transforming Event in a Mouse Model of t(12;13)(p13;q12) Acute Myeloid Leukemia
46. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
47. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
48. Therapy of older persons with acute myeloid leukaemia
49. Acute Myeloid Leukemias with Reciprocal Rearrangements Can Be Distinguished by Specific Gene Expression Profiles
50. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.